Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Gilead Sciences (GILD) stock in plain English

Free brief · no signupStart here
GILDPublished Nov 16, 2026
Gilead Sciences Inc
Healthcare · Drug Manufacturers - General
Manufactures prescription antiviral medications for HIV and viral hepatitis alongside cell therapies for complex cancers.
Assets:
Biktarvy franchiseGenerates over half of total net product sales globally
Kite Pharma cell therapyOperates dedicated CAR-T manufacturing facilities in California, Maryland, and Europe
18,000 global employeesWork across commercial operations, clinical development, and research hubs
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

31
OPS ScoreOperating finances
Latest quote
-1.45%$166.53
$206.55B
n/a (loss)
$31.06B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was GILD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Gilead Sciences (GILD) do?

Gilead Sciences Inc (GILD) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures prescription antiviral medications for HIV and viral hepatitis alongside cell therapies for complex cancers. Produces specialized antiviral therapies that treat the majority of the global population living with HIV. It is worth $206.55B on the market and sold $31.06B over the last year.

Market cap
$206.55B
P/E ratio
None (reported a loss)
Annual sales
$31.06B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 16, 2026

Brands and businesses behind GILD

  • Biktarvy: Treats HIV infection as a daily single tablet and generates over half of Gilead's pharmaceutical sales.
  • Descovy: Provides HIV treatment and pre-exposure prevention therapy through direct commercial pharmacy sales.
  • Veklury: Treats severe COVID-19 infections intravenously in hospital inpatient settings.
  • Trodelvy: Treats metastatic breast and urothelial cancer, earning revenue through specialized oncology sales.
  • Yescarta: Provides individualized cell therapy for large B-cell lymphoma manufactured specifically for each patient.
  • Epclusa: Cures chronic hepatitis C across all major genotypes, generating revenue from direct prescription sales.

GILD’s flags, in plain English

Each flag is a number from Gilead Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Wide Gross Margin

Gross margin of 80% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Cheap on Cash Flow

Priced at 15 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Pays You to Hold

Pays a 1.98% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Debt Is Driving

Heavy debt, 201% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about GILD

How big is Gilead Sciences?

Gilead Sciences’ market cap is $206.55B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $31.06B: what customers paid the company over the last year, before any costs.

What is GILD’s P/E ratio?

GILD has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with GILD?

More than half of the company's total revenue depends on a single HIV drug called Biktarvy. That is one risk on Gilead Sciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Gilead Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GILD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card